Company News: Page (1) of 1 - 04/21/17 Email this story to a friend. email article Print this page (Article printing at page facebook

Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C

- 95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR(12) with 8 weeks of treatment(1)- Together with pr... (April 21, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Presentors,Computers/Peripherals,Notebook/Laptop/Tablets,Business Issues,Presentation,Channel/Distribution,People,Events,USA,AES Attendees,Medicine,Disease,Surgery,Medication,Science,Medical,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved